157 related articles for article (PubMed ID: 37856184)
1. Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side-by-side comparison.
Menig S; Dinh A; Angus J; Tucker S; Leger KJ; Rushing T; Orgel E
Pediatr Blood Cancer; 2024 Jan; 71(1):e30716. PubMed ID: 37856184
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
Burke MJ; Zalewska-Szewczyk B
Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
[TBL] [Abstract][Full Text] [Related]
3. Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with acute lymphoblastic leukemia.
McCormick M; Lapinski J; Friehling E; Smith K
Pediatr Blood Cancer; 2021 Aug; 68(8):e29051. PubMed ID: 33860989
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Vagrecha A; Tao V; Corless R; Colon C; Redner A; Atlas M
Expert Rev Clin Pharmacol; 2023; 16(8):763-769. PubMed ID: 37294084
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
[TBL] [Abstract][Full Text] [Related]
6. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
7. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.
Cooper SL; Young DJ; Bowen CJ; Arwood NM; Poggi SG; Brown PA
Pediatr Blood Cancer; 2019 Aug; 66(8):e27797. PubMed ID: 31099154
[TBL] [Abstract][Full Text] [Related]
8. A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native
Odaman Al I; Özdemir N; Zengin Ersoy G; Bayram C; Vupa Çilengiroğlu Ö; Arslantaş E; Paslı Uysalol E; Ayçiçek A
J Oncol Pharm Pract; 2023 Sep; 29(6):1454-1460. PubMed ID: 36942380
[TBL] [Abstract][Full Text] [Related]
9. [Hypersensitivity reactions associated with the use of asparaginase in children with acute lymphoblastic leukemia].
Ovalle B P; Azócar M M; Nicklas D C; Villarroel C M; Morales V J
Andes Pediatr; 2021 Apr; 92(2):182-192. PubMed ID: 34106156
[TBL] [Abstract][Full Text] [Related]
10. Allergic reactions associated with pegaspargase in adults.
Chang A; Kim M; Seyer M; Patel S
Leuk Lymphoma; 2016 Jul; 57(7):1665-8. PubMed ID: 26461960
[TBL] [Abstract][Full Text] [Related]
11. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
[TBL] [Abstract][Full Text] [Related]
12. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
Sandley M; Angus J
Leuk Lymphoma; 2023 Apr; 64(4):776-787. PubMed ID: 36781296
[TBL] [Abstract][Full Text] [Related]
13. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
14. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
Alrazzak M; Beaupin LK; Kinyoun P; Barth M
J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
[TBL] [Abstract][Full Text] [Related]
15. Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
Beaupin LK; Bostrom B; Barth MJ; Franklin I; Jaeger R; Kamath P; Schreiber B; Bleyer A
Leuk Lymphoma; 2017 Apr; 58(4):766-772. PubMed ID: 27643446
[TBL] [Abstract][Full Text] [Related]
16. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
[TBL] [Abstract][Full Text] [Related]
17. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
18. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
19. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
Sikorska-Fic B; Makowska K; Rokicka-Milewska R
Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
[TBL] [Abstract][Full Text] [Related]
20. Reply to: Comment on: "Premedication prior to PEG-asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia".
McCormick M; Friehling E; Smith K
Pediatr Blood Cancer; 2022 Nov; 69(11):e29694. PubMed ID: 35338677
[No Abstract] [Full Text] [Related]
[Next] [New Search]